Results 21 to 30 of about 10,985 (213)

Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. [PDF]

, 2009
OBJECTIVE: To identify risk factors for in-hospital mortality in patients treated for visceral leishmaniasis (VL) in Uganda. METHODS: Retrospective analysis of VL patients' clinical data collected for project monitoring by Médecins Sans Frontières in ...
Bern, Bryceson, Chappuis, Collin, Croft, Delgado, Desjeux, Guerin, Jamjoom, Lyons, Moore, Mueller, Mueller, Olliaro, Ritmeijer, Ritmeijer, Seaman, Sundar, Thakur, Veeken, WHO   +20 more
core   +3 more sources

Induction of Apoptosis by Miltefosine in Iranian Strain of Leishmania infantum Promastigotes [PDF]

Iranian Journal of Parasitology, 2009
Background: Miltefosine is a new drug of choice for the treatment of visceral leishmaniasis. Numerous experi­mental studies have shown miltefosine is effective on Leishmania donovani, however, effectiveness of miltefos­ine in treatment of L.
S Khademvatan, MJ Gharavi, L Akhlaghi, A Samadikuchaksaraei, K Mousavizadeh, R Hadighi, J Saki   +6 more
doaj   +1 more source

Biological risk assessment of miltefosine in concomitant infection with opportunistic toxoplasmosis

Journal of Infection in Developing Countries, 2019
Introduction: Although miltefosine is the first line for treatment of leishmaniasis, it could have multiple un-recognized effects if any infection accidentally takes place during therapy.
Ashraf M Barakat, Amal E Saafan, Samuel T Melek, Tahany S Behour, Nehal M Khairy, Ahmed S Khairalla   +5 more
doaj   +1 more source

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. [PDF]

, 2011
Due to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human ...
Aderie, Endashaw Mengistu, Chane, Solomon, Collin, Simon M, Davidson, Robert N, Piening, Turid, Ritmeijer, Koert, ter Horst, Rachel   +6 more
core   +2 more sources

The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil

Memorias do Instituto Oswaldo Cruz, 2011
The in vitro leishmanicidal activity of miltefosine® (Zentaris GmbH) was assessed against four medically relevant Leishmania species of Brazil: Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, Leishmania (Viannia) guyanensis and ...
Eliane de Morais-Teixeira, Quesia Souza Damasceno, Mariana Kolos Galuppo, Alvaro José Romanha, Ana Rabello   +4 more
doaj   +1 more source

Topical Sustained Delivery of Miltefosine Via Drug-Eluting Contact Lenses to Treat Acanthamoeba Keratitis

Pharmaceutics, 2022
This study aimed to develop a miltefosine-eluting contact lens (MLF-CL) device that would allow sustained and localized miltefosine release for the treatment of Acanthamoeba keratitis. MLF-CLs were produced in three different miltefosine doses by solvent-
Lin Chen, Liangju Kuang, Amy E. Ross, Wissam Farhat, Nikolay Boychev, Sina Sharfi, Levi N. Kanu, Longqian Liu, Daniel S. Kohane, Joseph B. Ciolino   +9 more
doaj   +1 more source

Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol

Parasites & Vectors, 2021
Background Leishmania infantum is the most important etiological agent of visceral leishmaniasis in the Americas and Mediterranean region, and the dog is the main host.
Gustavo Gonçalves, Monique Paiva Campos, Alessandra Silva Gonçalves, Lia Carolina Soares Medeiros, Fabiano Borges Figueiredo   +4 more
doaj   +1 more source

Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. [PDF]

PLoS Neglected Tropical Diseases, 2015
BACKGROUND:Recent studies have shown significant decline in the final cure rate after miltefosine treatment in visceral leishmaniasis. This study evaluates the efficacy of miltefosine in the treatment of post kala-azar dermal leishmaniasis (PKDL ...
V Ramesh, Ruchi Singh, Kumar Avishek, Aditya Verma, Deepak Kumar Deep, Sandeep Verma, Poonam Salotra   +6 more
doaj   +1 more source

Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice

Revista da Sociedade Brasileira de Medicina Tropical, 2014
Introduction The treatment of leishmaniasis ischallenging, given the difficulties in drug administration and resistance. Therefore, we chose to test the efficacy of miltefosine combined with pentoxifylline.
Ana Angélica Amorim Santarem, Gabriel Frizon Greggianin, Rafaela Garcia Debastiani, Jefferson Bruno Pereira Ribeiro, Demerson Andre Polli, Raimunda Nonata Ribeiro Sampaio   +5 more
doaj   +1 more source

Lipid raft‐disrupting miltefosine preferentially induces the death of colorectal cancer stem‐like cells

Clinical and Translational Medicine, 2021
Background Lipid rafts (LRs), cholesterol‐enriched microdomains on cell membranes, are increasingly viewed as signalling platforms governing critical facets of cancer progression.
So‐Yeon Park, Jee‐Heun Kim, Jang‐Hyun Choi, Choong‐Jae Lee, Won‐Jae Lee, Sehoon Park, Zee‐Yong Park, Jeong‐Heum Baek, Jeong‐Seok Nam   +8 more
doaj   +1 more source